SLV-306. Solvay.
SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for the potential treatment of essential hypertension and congestive heart failure. The compound is currently undergoing phase II clinical trials in Belgium.
Tabrizchi
Reza
R
Memorial University of Newfoundland, Faculty of Medicine, Basic Medical Sciences, Health Sciences Centre, St John's Newfoundland, A1B 3V6 Canada. rtabrizc@morgan.ucs.mun.ca
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000072396:Endothelin-Converting Enzymes; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism; D008666:Metalloendopeptidases; D015260:Neprilysin / Q000037:antagonists & inhibitors
D000959:Antihypertensive Agents; D001552:Benzazepines; C405520:SLV 306; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D015260:Neprilysin; D000072396:Endothelin-Converting Enzymes